Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

Andrés Gómez-De León, MD, Dalila Marisol Alvarado Navarro, MD, Cesar O Pezina Cantú, MD, Perla R. Colunga Pedraza, MD, David Gomez-Almaguer, MD, Rosario Salazar Riojas, Chem., Olga Graciela Cantu Rodriguez, MD, Luz del Carmen Tarín Arzaga, MD, Jose Carlos Jaime, MD PhD, Cesar Homero Gutierrez-Aguirre, PhD

Blood (2019) 134 (Supplement_1): 4476.

https://doi.org/10.1182/blood-2019-129516

Published: 2019

Journal Articles

Comparing Costs Associated to Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy in HCMV-Seropositive Patients Who Undergone to Hemopoietic Stem Cells Transplantation

Oscar Borsani, MD, Daniele Lilleri, Elisa Gabanti, Gabriela Cassinelli, Anna Amelia Colombo, MD, Daniela Caldera, MD, Emilio Paolo Alessandrino, MD, Paolo Bernasconi, MD

Blood (2019) 134 (Supplement_1): 5643.

https://doi.org/10.1182/blood-2019-124121

Published: 2019

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Ujunwa Cynthia Okoye-Okafor, MS,PhD, Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Joseph J Saad, MSc, BSc, Lumie Benard, Victor Thiruthuvanathan, M.S, Sally Cole, Madhuri Tatiparthy, M.S., Stephen Ruiz, B.Sc, Stefanie DeFronzo, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Amit Verma, MBBS, Aditi Shastri, MD, Caroline A Heckman, PhD, Britta Will, PhD

Blood (2019) 134 (Supplement_1): 1280.

https://doi.org/10.1182/blood-2019-131461

Published: 2019

Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM

Blood (2019) 134 (Supplement_1): 2914.

https://doi.org/10.1182/blood-2019-128755

Published: 2019

Journal Articles

To Assess the Appropriateness of the Venous Thromboembolism (VTE) Prophylaxis Agent Used Based on the VTE Risk Stratification in Hospitalised Acutely Ill Medical Patients

Maitreyee Rai, MBBS, Jian Liang Tan, MD, Meghana Parsi, MD, Malvika Duphare, DO, Mylene S. Go, MD

Blood (2019) 134 (Supplement_1): 2444.

https://doi.org/10.1182/blood-2019-122402

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

Journal Articles

Reconstituted Bay 81-8973 Factor VIII Stability Supports Its Suitability for Continuous Infusion for up to 24 Hours

John M. Teare, PhD, Jared Trefethen, Stephen Garger, Prasad Mathew, MD

Blood (2018) 132 (Supplement 1): 5043.

https://doi.org/10.1182/blood-2018-99-114976

Published: 2018

Journal Articles

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

Gennadii M. Galstian, Olesya A. Polevodova, MD, Vladimir Yu. Zorenko, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2018-99-115685

Published: 2018

Journal Articles

Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide

Mohammed M Elayan, PharmD, Carlos R. Bachier, MD, Minoo Battiwalla, MD, Darby Siler, PharmD

Blood (2018) 132 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2018-99-112256

Published: 2018

Journal Articles

Proteomics Pathways of Sickle Cell Anemia (P2SCA): A Comprehensive Analysis By Liquid Chromatography Mass Spectrometry of Erythrocyte Membrane Proteins Characterized from the Muhimbili Sickle Cell Programme, Tanzania

Haddy KS Fye, PhD BSc, Paul Mrosso, Frédéric B Piel, PhD, Simon Davis, Roman Fischer, Gration Rwegasira, Benedikt Kessler, Julie Makani, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2018-99-114650

Published: 2018

Journal Articles

Thalidomide Does Not Compromise Mobilization with Cytokine Alone in Multiple Myeloma after Triplet Induction Regimen

Matevz Skerget, MD PhD, Matjaz Sever, MD PhD, Barbara Skopec, MD PhD

Blood (2018) 132 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2018-99-116124

Published: 2018

Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2018-99-113590

Published: 2018

Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD

Blood (2018) 132 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2018-99-113161

Published: 2018

Journal Articles

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Elise A. Chong, MD, Bruce L Levine, PhD, Stephan A. Grupp, MD PhD, Megan Davis, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Whitney Lynn Gladney, PhD, Noelle V. Frey, MD, David L. Porter, MD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 197.

https://doi.org/10.1182/blood-2018-197

Published: 2018

Journal Articles

Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield

Nosha Farhadfar, MD, Jack W. Hsu, MD, Brent R. Logan, PhD, Jennifer A. Sees, MPH, Pintip Chitphakdithai, PhD, Dennis L. Confer, MD, Michael A. Pulsipher, MD, Nirali N. Shah, MD, Galen E. Switzer, PhD, Bronwen E. Shaw, MD PhD, John R. Wingard, MD

Blood (2018) 132 (Supplement 1): 193.

https://doi.org/10.1182/blood-2018-193

Published: 2018

Journal Articles

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

John L Vaughn, MD, Misty Lamprecht, MS, Ying Huang, MA, MS, Mirela Anghelina, Joan-Miquel Balada-Llasat, PharmD, PhD, Zeinab El Boghdadly, MBBCh, Rachel Childs, Preeti Pancholi, PhD, Leslie A Andritsos, MD

Blood (2017) 130 (Supplement 1): 3211.

https://doi.org/10.1182/blood.V130.Suppl_1.3211.3211

Published: 2017

Journal Articles

Pharmacokinetics of Treosulfan in Patients with Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation — a Comparison of Two Formulations and Correlation with Clinical Outcomes

Alok Srivastava, MD, Ezhilpavai Mohanan, Msc, Raveen Stephen Stallon Illangeswaran, M.Sc.,, Carl Panetta, PhD, Kavitha M Lakshmi, MSc, Anu Korula, MD DM, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Poonkuzhali Balasubramanian, MSc, PhD

Blood (2017) 130 (Supplement 1): 3219.

https://doi.org/10.1182/blood.V130.Suppl_1.3219.3219

Published: 2017

Journal Articles

Resource Utilization Using Micro-Costing Method and Cost Effectiveness Analysis of Treatment of Acute Promyelocytic Leukemia with Generic Arsenic-Trioxide

Aniket Bankar, MD, Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Nisham PN, MD DM, Anu Korula, MD DM, Aby Abraham, MD DM, Alok Srivastava, MD, Sezlian S, Visali Jeyaseelan, PhD, Jasmine Prasad, MD, Biju George, MDDM, Vikram Mathews, MD DM

Blood (2017) 130 (Supplement 1): 3392.

https://doi.org/10.1182/blood.V130.Suppl_1.3392.3392

Published: 2017

NARROW

Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting

Comparing Costs Associated to Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy in HCMV-Seropositive Patients Who Undergone to Hemopoietic Stem Cells Transplantation

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

To Assess the Appropriateness of the Venous Thromboembolism (VTE) Prophylaxis Agent Used Based on the VTE Risk Stratification in Hospitalised Acutely Ill Medical Patients

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Reconstituted Bay 81-8973 Factor VIII Stability Supports Its Suitability for Continuous Infusion for up to 24 Hours

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide

Proteomics Pathways of Sickle Cell Anemia (P2SCA): A Comprehensive Analysis By Liquid Chromatography Mass Spectrometry of Erythrocyte Membrane Proteins Characterized from the Muhimbili Sickle Cell Programme, Tanzania

Thalidomide Does Not Compromise Mobilization with Cytokine Alone in Multiple Myeloma after Triplet Induction Regimen

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

Pharmacokinetics of Treosulfan in Patients with Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation — a Comparison of Two Formulations and Correlation with Clinical Outcomes

Resource Utilization Using Micro-Costing Method and Cost Effectiveness Analysis of Treatment of Acute Promyelocytic Leukemia with Generic Arsenic-Trioxide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only